Day: April 14, 2022

TORONTO, April 14, 2022 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) announced today its production and sales results for the first quarter of 2022. First Quarter Production Highlights:Consolidated saleable gold equivalent production and sales of 29,631 and 28,280 ounces respectively; 12,384 ounces of saleable gold production at Björkdal, highest quarterly production result since Q2 2019; and 12,134 ounces of gold sold at Björkdal, highest quarterly sales result since Q3 2019.Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay’s solid start to the year puts us on course to achieve our 2022 production guidance. The continued excellent operational results demonstrate the sustainability and incremental growth at both sites with a...

Randomized Phase 2 clinical study evaluating SRF388 in first-line hepatocellular carcinoma in clinical collaboration with Roche Single-arm Phase 2 clinical study evaluating SRF388 as a monotherapy in patients with previously-treated non-small-cell lung cancer CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the initiation of two Phase 2 clinical studies evaluating SRF388, a potential first-in-class antibody against IL-27. The trials include a randomized Phase 2 clinical study evaluating SRF388 in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC) and a Phase 2 monotherapy study in patients...

SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“SGMD” or the ‎‎“Company”) (TSXV:SGMD), ‎an acquisition-oriented medical device company serving the global injury and surgery recovery (known as recovery science) market, announced today it has executed a binding agreement to acquire a portfolio of medical device intellectual property (the “Product IP”) which has already been approved for distribution in the U.S. by the U.S. Food & Drug Administration (FDA). The Product IP portfolio consists of (1) transcutaneous electrical nerve stimulation (TENS) technology, (2) neuromuscular electrical stimulation technology (NEMS), and (3) drug delivery electrode technology, three key technologies used in medical device recovery science.As part of the Company’s corporate strategy to acquire products...

Gilmore O’Neill Editas Medicine today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President and Chief Executive Officer.James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has appointed Dr. Gilmore O’Neill, M.B., M.M.Sc., as President and Chief Executive Officer. James C. Mullen will serve as Executive Chairman of the Company’s Board of Directors. These changes are effective June 1, 2022. Dr. O’Neill brings to Editas nearly 20 years of experience in genetic medicine, neurobiology, and clinical development. Dr. O’Neill also has a track record of driving and leading several of biotech’s most successful clinical programs...

The Corporation continues to intersect significant gold mineralization at depth MONTREAL, April 14, 2022 (GLOBE NEWSWIRE) — TOMAGOLD CORPORATION (TSXV: LOT) (OTCQB: TOGOF) (“TomaGold” or the “Corporation”) is pleased to report the last results of its 11,500-metre drilling program on its wholly-owned Obalski property in Chibougamau, Quebec. In this latest phase, the Corporation drilled five holes for a total of 2,409 m. Table 1: Best drilling resultsHole Zone Section From(m) To(m) Length(m)* Au(g/t) Ag(g/t) Cu(%) Depth(m)OBS-22-016 A-Po 300+00 E 258.35 283.50 25.15 0.31 0.58 0.06 200OBS-22-017 C 300+00 E 193.20 194.00 0.80 3.83 8.30 0.42 165  A-Po   297.95 314.90 16.95 0.33 0.09 0.03 260  A-Po   343.90 353.25 9.35 6.07 3.29 0.08 295Including     349.90 350.80 0.90 60.60 31.80 0.60  OBS-22-018 C 300+00 E 306.85 310.45 3.60 0.43 0.63 0.02 285OBS-22-019 A-Po 175+00...

TRAINERS’ HOUSE PLC, STOCK EXCHANGE RELEASE, 14 APRIL 2022 AT 14:15 The number of shares reported by the company on 4 April 2022 was incorrect. The correct number of shares is 2,147,826, which is two shares less than previously announced. The error was caused by a human error in the third-party book-entry system. TRAINERS’ HOUSE PLC Information Saku Keskitalo, CFO, tel. +358 404 111 111 DISTRIBUTION NASDAQ Helsinki Key media www.trainershouse.fi – Investors

Event Features Discussion with Glenn Chertow, M.D., MPH, Professor of Medicine at Stanford University School of Medicine LOS ALTOS, Calif., April 14, 2022 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that there will be a Key Opinion Leader (KOL) Event discussing “Novel Treatments in Kidney Disease” with leading physician and thought leader, Glenn Chertow, M.D., MPH, Professor of Medicine at Stanford University School of Medicine and, by courtesy, Professor of Epidemiology and Population Health. Dr. Chertow also serves as a member of Unicycive Therapeutics’ Scientific Advisory Board. The event will be moderated by Elemer Piros, Ph.D., Senior Biotechnology Analyst at ROTH Capital, who covers Unicycive Therapeutics. Event...

EDMONTON, Alberta, April 14, 2022 (GLOBE NEWSWIRE) — Visionstate Corp. (TSXV: VIS) (“Visionstate” or the “Company”) is pleased to provide the following update on the growth of its Internet of Things (IoT) application which is quickly gaining traction in the facility management sector under the branded name, WANDA™. WANDA™ has quickly become an important tool in the fight against COVID-19 and other diseases as the sixth wave of the virus continues to create health concerns across Canada and beyond. WANDA™ is a mobile application, incorporating QR code functionality, that tracks cleaning and maintenance activities and measures those activities against new and more stringent protocols. “We are very pleased with the growth of Visionstate IoT Inc.,” said Company CEO John Putters. “WANDA™ is quickly becoming the primary tool for businesses,...

BEIJING, April 14, 2022 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 (the “2021 Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). The 2021 Annual Report, which contains Luckin Coffee’s audited consolidated financial statements prepared under U.S. GAAP as of and for the fiscal year ended December 31, 2021, can be accessed on the SEC’s website and on the Company’s investor relations website at https://investor.lkcoffee.com/. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions...